What question did this study set out to answer?

This study investigates the prognostic impact of genomic co-alterations, particularly TP53, in early-stage EGFR-mutated non-small cell lung cancer.

Clinical impact of genomic co-mutation profiles including TP53 in resected early-stage EGFR -mutated NSCLC: LC-SCRUM-Advantage.

View Full Paper

Ask AI

Bookmark

This study investigates the prognostic impact of genomic co-alterations, particularly TP53, in early-stage EGFR-mutated non-small cell lung cancer.
Prospective genomic screening in resected NSCLC patients via LC-SCRUM-Advantage.
Tumor specimens analyzed for co-alterations using Oncomine Precision Assay.
Clinico-genomic characteristics and survival outcomes were evaluated.
Among 1052 patients, 327 had EGFR-mutated adenocarcinoma with common mutations: 42% 19del, 47% L858R.
Co-alterations detected in 41% of tumors, with TP53 present in 19%.
Higher PD-L1 positivity in TP53-mutated tumors (60%) vs wild-type (39%; p = 0.007).

No takes yet. Share an insight, caveat, or question.

Randomized trial evaluates genomic co-alterations in early-stage EGFR-mutated NSCLC, suggesting prognostic relevance for treatment planning.

Yoh et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized trial evaluates genomic co-alterations in early-stage EGFR-mutated NSCLC, suggesting prognostic relevance for treatment planning.